Cencora Inc.COR
▲ PositiveCapitalrelevance
Beat Q3 EPS estimates and raised fiscal 2026 EPS guidance.
Impact on stocks 2
Health Care
Cencora Inc.
Mednax IncMD
Mentioned
Cencora Beats Q3 Estimates, Raises Fiscal 2026 EPS Guidance
Earnings
Cencora reported third-quarter fiscal 2026 adjusted earnings per share of $4.48, beating the Zacks Consensus Estimate of $4.37 by 2.5%, and raised its full-year adjusted EPS guidance to $17.75-$17.95 from $17.70-$17.90. Revenues rose 5.1% year over year to $84.76 billion, slightly missing the consensus estimate of $84.89 billion, with growth driven by its U.S. Healthcare Solutions segment, which saw revenues increase 4.9% to $74.9 billion, and International Healthcare Solutions, which grew 5.9% to $7.7 billion. Adjusted operating income advanced 17% to $1.24 billion, and the company now projects adjusted operating income growth of 13-14% for the fiscal year. Since the earnings release, estimates have trended downward, and Cencora holds a Zacks Rank #3 (Hold).
Cencora Inc.Beat Q3 EPS estimates and raised fiscal 2026 EPS guidance.
Mednax Inc